DGX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

2.75B

+5.05%

2.357

+5.71%

2.76B

+3.99%

2.364

+6.97%

2.88B

+4.15%

2.760

+5.34%

Estimates Revision

The market is revising Upward the revenue expectations for Quest Diagnostics Incorporated (DGX) for FY2025, with the revenue forecasts being adjusted by 1.07% over the past three months. During the same period, the stock price has changed by -5.23%.

Revenue Estimates for FY2025

Revise Upward

+1.07%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.6%

In Past 3 Month

Stock Price

Go Down

-5.23%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast DGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DGX is 200.78 USD with a low forecast of 190.00 USD and a high forecast of 215.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

7 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

190.00

Averages

200.78

High

215.00

Current: 0.000

Low

190.00

Averages

200.78

High

215.00

Piper Sandler

Neutral

maintain

$190 -> $200

2025-10-27

Reason

Piper Sandler

Price Target

$190 -> $200

2025-10-27

maintain

Neutral

Reason

Piper Sandler raised the firm's price target on Quest Diagnostics to $200 from $190 following quarterly results. The firm keeps a Neutral rating on the shares.

Morgan Stanley

Erin Wright

Overweight

maintain

$191 -> $207

2025-10-22

Reason

Morgan Stanley

Erin Wright

Price Target

$191 -> $207

2025-10-22

maintain

Overweight

Reason

Morgan Stanley analyst Erin Wright raised the firm's price target on Quest Diagnostics (DGX) to $207 from $191 and keeps an Overweight rating on the shares. Another "beat & raise" quarter was "encouraging," but shares slid as expectations were high and margin pressure was seen in Q3. The firm, which cites a "robust" utilization environment and relative policy insulation for its hiked target, thinks utilization strength should be a positive read for Labcorp's (LH) upcoming report on October 28, but notes that the bar may be raised for labs.

Truist

Hold

maintain

$195 -> $205

2025-10-22

Reason

Truist

Price Target

$195 -> $205

2025-10-22

maintain

Hold

Reason

Truist raised the firm's price target on Quest Diagnostics to $205 from $195 and keeps a Hold rating on the shares. The company posted solid Q3 results ahead of consensus expectations on the top and bottom-lines with FY25 nudged higher as its core trends remain solid with organic volumes ahead of the firm's thinking, better revenue, and a continued tailwind from testing, with the organic revenue guide raised, the analyst tells investors in a research note.

Barclays

Equal Weight

maintain

$190 -> $195

2025-10-22

Reason

Barclays

Price Target

$190 -> $195

2025-10-22

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Quest Diagnostics to $195 from $190 and keeps an Equal Weight rating on the shares post the Q3 report. The company reported "another solid print," the analyst tells investors in a research note. The firm views the post-earnings share selloff as a function of investor positioning given the strength in core tools names and improving sentiment versus moving away from the more defensive labs.

Leerink

Outperform

maintain

$203 -> $210

2025-10-21

Reason

Leerink

Price Target

$203 -> $210

2025-10-21

maintain

Outperform

Reason

Leerink raised the firm's price target on Quest Diagnostics to $210 from $203 and keeps an Outperform rating on the shares. Q3 results were "another proof point of the near-Goldilocks environment in the lab space," according to the analyst, who sees the stock action following "another strong quarter" as more likely a result of rotation than any new fundamental worries.

Jefferies

Buy

maintain

$200 -> $215

2025-10-21

Reason

Jefferies

Price Target

$200 -> $215

2025-10-21

maintain

Buy

Reason

Jefferies raised the firm's price target on Quest Diagnostics to $215 from $200 and keeps a Buy rating on the shares. Sales and EPS beat consensus and fiscal year guidance was raised, notes the analyst, who is "encouraged" by the organic acceleration and "optimistic" for the Haystack MRD test ramp in 2026.

Valuation Metrics

The current forward P/E ratio for Quest Diagnostics Inc (DGX.N) is 17.04, compared to its 5-year average forward P/E of 15.64. For a more detailed relative valuation and DCF analysis to assess Quest Diagnostics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

15.64

Current PE

17.04

Overvalued PE

17.62

Undervalued PE

13.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.80

Current EV/EBITDA

11.32

Overvalued EV/EBITDA

11.87

Undervalued EV/EBITDA

9.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.72

Current PS

1.71

Overvalued PS

1.87

Undervalued PS

1.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 4456.93% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1536.08% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 4456.93% over the last month.

Sold

Bought

DGX News & Events

Events Timeline

No data

News

8.0

01-09Barron's

Clinical Labs Aim to Prevent Upcoming Medicare Reductions

8.0

01-09NASDAQ.COM

Quest Diagnostics (DGX) Dividend Yield Estimated at 1.80%

3.5

01-06PRnewswire

Quest Diagnostics Showcases ctDNA MRD Testing Advances at ASCO 2026

People Also Watch

Frequently Asked Questions

What is Quest Diagnostics Inc (DGX) stock price today?

The current price of DGX is 174.44 USD — it has decreased -1.86 % in the last trading day.

What is Quest Diagnostics Inc (DGX)'s business?

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.

What is the price predicton of DGX Stock?

What is Quest Diagnostics Inc (DGX)'s revenue for the last quarter?

Quest Diagnostics Inc revenue for the last quarter amounts to 2.82B USD, increased 13.18 % YoY.

What is Quest Diagnostics Inc (DGX)'s earnings per share (EPS) for the last quarter?

Quest Diagnostics Inc. EPS for the last quarter amounts to 2.15 USD, increased 8.04 % YoY.

What changes have occurred in the market's expectations for Quest Diagnostics Inc (DGX)'s fundamentals?

How many employees does Quest Diagnostics Inc (DGX). have?

Quest Diagnostics Inc (DGX) has 45000 emplpoyees as of January 10 2026.

What is Quest Diagnostics Inc (DGX) market cap?

Today DGX has the market capitalization of 19.41B USD.